Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
The ONKOTEV score predicts the risk of venous thromboembolism in cancer patients.
Read Full NewsJanelle Wagner, PhD, a clinical psychologist and research professor at the Medical University of South Carolina, provided clinical insights on a recently presented study on whether elevated ADHD symptoms impact post epilepsy surgery seizure freedom.
Here's some of what is coming soon to NeurologyLive® this week.
A new large-scale analysis revealed that patients with identical EDSS scores can exhibit distinct patterns of functional impairment, identified using artificial intelligence–based clustering algorithms.
Rheumatology in 2025: Year in Review
Early Week 2 Response Predicts Sustained Benefit with Adjunct Cariprazine in MDD
KDIGO Releases New Guideline for Anemia in Chronic Kidney Disease
Chronic Kidney Disease Paired With Social Frailty May Increase Depression Risk
1.
Providing essential cancer care to rural communities
2.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
3.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
4.
Treatment of Smoldering Myeloma Cuts Progression Rate in Half
5.
How Do Younger People Fare With Stool Tests for CRC Screening?
1.
Benefits of Neutrophilia: Harnessing the Power of White Blood Cells to Promote Health and Well-Being
2.
Nipple-Sparing Mastectomy: Oncologic Safety and Patient Selection Review
3.
Chemotherapy Advances: Albumin I.V., Trastuzumab, Liposomal Doxorubicin & More
4.
The Truth About Marijuana and Its Effect on Mental Health
5.
Unlocking the Potential of Glofitamab: A Novel Treatment for Cancer
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
4.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge